CareDx Inc. has announced the launch of HistoMap Kidney, a tissue-based molecular test designed to characterize rejection types and enhance the clinical utility of kidney biopsy results. The test uses gene expression profiling to provide deeper insights into immune activity and rejection phenotypes, complementing traditional pathology with molecular information. HistoMap Kidney is expected to be available in early 2026 through a clinical study. Additionally, CareDx presented new data at the American Society of Nephrology (ASN) Kidney Week 2025, including studies on the use of cell-free DNA (AlloSure) and gene expression profiling in kidney transplant care. Featured presentations highlighted the integration of AlloSure with clinical parameters through the AI-powered AlloView (now AlloSure Plus) tool for predicting antibody-mediated rejection, as well as research on donor-derived cell-free DNA in kidney transplant recipients. Some results were presented during poster sessions at ASN Kidney Week 2025, while the HistoMap Kidney clinical study is scheduled for the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105412097) on November 06, 2025, and is solely responsible for the information contained therein.
Comments